WO2007081302A3 - Miméticorps de la glp-1 humaine, compositions, procédés et utilisations - Google Patents

Miméticorps de la glp-1 humaine, compositions, procédés et utilisations Download PDF

Info

Publication number
WO2007081302A3
WO2007081302A3 PCT/US2005/046884 US2005046884W WO2007081302A3 WO 2007081302 A3 WO2007081302 A3 WO 2007081302A3 US 2005046884 W US2005046884 W US 2005046884W WO 2007081302 A3 WO2007081302 A3 WO 2007081302A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
glp
compositions
mimetibody
mimetibodies
Prior art date
Application number
PCT/US2005/046884
Other languages
English (en)
Other versions
WO2007081302A2 (fr
Inventor
Karyn T O'neil
Kristen Picha
Original Assignee
Centocor Inc
Karyn T O'neil
Kristen Picha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc, Karyn T O'neil, Kristen Picha filed Critical Centocor Inc
Priority to JP2008504018A priority Critical patent/JP2008546373A/ja
Priority to BRPI0520168-3A priority patent/BRPI0520168A2/pt
Priority to EA200702093A priority patent/EA200702093A1/ru
Priority to EP05858723A priority patent/EP1871811A4/fr
Priority to MX2007011975A priority patent/MX2007011975A/es
Priority to CA002603359A priority patent/CA2603359A1/fr
Priority to AU2005339797A priority patent/AU2005339797A1/en
Publication of WO2007081302A2 publication Critical patent/WO2007081302A2/fr
Priority to IL186307A priority patent/IL186307A0/en
Priority to NO20075272A priority patent/NO20075272L/no
Publication of WO2007081302A3 publication Critical patent/WO2007081302A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne au moins un nouveau miméticorps de la GLP-1 humaine ou une partie ou un variant spécifié, comprenant des acides nucléiques isolés qui codent pour au moins un miméticorps de la GLP-1 ou une partie ou un variant spécifié, un miméticorps de la GLP-1 ou une partie ou des variants spécifiés, des vecteurs, des cellules hôtes, des animaux ou des végétaux transgéniques, ainsi que des procédés pour les produire et les utiliser, y compris des compositions, des procédés et des dispositifs thérapeutiques.
PCT/US2005/046884 2004-03-31 2005-12-22 Miméticorps de la glp-1 humaine, compositions, procédés et utilisations WO2007081302A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2008504018A JP2008546373A (ja) 2005-03-28 2005-12-22 ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
BRPI0520168-3A BRPI0520168A2 (pt) 2005-03-28 2005-12-22 mimeticorpos de glp-1 humanos, composiÇÕes, mÉtodos e usos
EA200702093A EA200702093A1 (ru) 2004-03-31 2005-12-22 Антитела-миметики glp-1 человека, композиции, способы и их применение
EP05858723A EP1871811A4 (fr) 2005-03-28 2005-12-22 Mimeticorps de la glp-1 humaine, compositions, procedes et utilisations
MX2007011975A MX2007011975A (es) 2005-03-28 2005-12-22 Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos.
CA002603359A CA2603359A1 (fr) 2005-03-28 2005-12-22 Mimeticorps de la glp-1 humaine, compositions, procedes et utilisations
AU2005339797A AU2005339797A1 (en) 2005-03-28 2005-12-22 Human GLP-1 mimetibodies, compositions, methods and uses
IL186307A IL186307A0 (en) 2005-03-28 2007-09-25 Human glp-1 mimetibodies, compositions, methods and uses
NO20075272A NO20075272L (no) 2005-03-28 2007-10-15 Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US2005/097175 2005-03-28
US2005097175 2005-03-28

Publications (2)

Publication Number Publication Date
WO2007081302A2 WO2007081302A2 (fr) 2007-07-19
WO2007081302A3 true WO2007081302A3 (fr) 2008-11-13

Family

ID=38256744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/046884 WO2007081302A2 (fr) 2004-03-31 2005-12-22 Miméticorps de la glp-1 humaine, compositions, procédés et utilisations

Country Status (12)

Country Link
EP (1) EP1871811A4 (fr)
JP (1) JP2008546373A (fr)
KR (1) KR20080005378A (fr)
CN (1) CN101389346A (fr)
AU (1) AU2005339797A1 (fr)
BR (1) BRPI0520168A2 (fr)
CA (1) CA2603359A1 (fr)
CR (1) CR9481A (fr)
IL (1) IL186307A0 (fr)
MX (1) MX2007011975A (fr)
NO (1) NO20075272L (fr)
WO (1) WO2007081302A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30820A1 (es) 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
CN111574583B (zh) * 2020-04-10 2021-06-25 上海海路生物技术有限公司 蛋白复性试剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US20040053370A1 (en) * 2000-12-07 2004-03-18 Wolfgang Glaesner GLP-1 Fusion Proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545608A4 (fr) * 2002-06-28 2006-09-13 Centocor Inc Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
CA2490411A1 (fr) * 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees
EP1644416A4 (fr) * 2003-06-30 2007-08-29 Centocor Inc Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
JP2008537873A (ja) * 2004-03-31 2008-10-02 セントカー・インコーポレーテツド ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US20040053370A1 (en) * 2000-12-07 2004-03-18 Wolfgang Glaesner GLP-1 Fusion Proteins

Also Published As

Publication number Publication date
IL186307A0 (en) 2008-01-20
CN101389346A (zh) 2009-03-18
EP1871811A2 (fr) 2008-01-02
CR9481A (es) 2009-01-14
JP2008546373A (ja) 2008-12-25
BRPI0520168A2 (pt) 2009-04-22
EP1871811A4 (fr) 2009-07-22
AU2005339797A1 (en) 2007-07-19
MX2007011975A (es) 2008-03-14
KR20080005378A (ko) 2008-01-11
NO20075272L (no) 2007-12-28
CA2603359A1 (fr) 2007-07-19
WO2007081302A2 (fr) 2007-07-19

Similar Documents

Publication Publication Date Title
WO2005097175A3 (fr) Corps mimetiques glp-1 humains, compositions, procedes et utilisations
WO2008011446A3 (fr) Mimétiques de la glp-1 humaine, compositions, procédés et utilisations
WO2005081687A3 (fr) Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes
WO2007046834A3 (fr) Agonistes glp-1, compositions, procedes et utilisations
WO2004002417A3 (fr) Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
WO2005032460A3 (fr) Mimeticorps de noyau charniere mimetiques de l'epo humaine, compositions, procedes et applications correspondantes
WO2003084477A3 (fr) Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
WO2006124451A3 (fr) Anticorps anti-il-13, compositions, procedes et utilisations
WO2005028511A3 (fr) Anticorps anti-amyloides, compositions, procedes et utilisations
LUC00121I1 (fr)
MX2010004179A (es) Anticuerpos anti-amiloide, composiciones, metodos y usos.
WO2005005604A3 (fr) Proteines derivees de l'immunoglobuline anti-cible et genetiquement modifiees, compositions, procedes et utilisations
WO2002072788A3 (fr) Proteines provenant de l'immunoglobuline associees a la bronchopneumopathie chronique obstructive, compositions, procedes et utilisations
WO2005062881A3 (fr) Therapie genique faisant intervenir des vecteurs de transposon
WO2009133573A3 (fr) Formulation homéopathique
WO2003086451A8 (fr) Proteines derivees de l'immunoglobuline anti il-13 associees a l'asthme, compositions, procedes et utilisations associes
WO2006036745A3 (fr) Proteines derivees de l'immunoglobuline specifiques de il-23p40, compositions, epitopes, procedes et utilisations
WO2002012501A3 (fr) Anticorps anti-integrines doubles, compositions, procedes et utilisations associes
WO2005112597A3 (fr) Plantes transgeniques exprimant des proteines a inteine modifiee et des procedes associes destines a la production bio-pharmaceutique
WO2004067567A3 (fr) Anticorps diriges contre le virus dengue, compositions, methodes et utilisations correspondantes
WO2007076319A3 (fr) Corps mimetiques humains glp-1 et compositions pour traiter l’obesite et les troubles associes, procedes et utilisations
WO2010000851A3 (fr) Procédés pour moduler l’angiogenèse via la dystrophine dp71
WO2006039638A3 (fr) Traitement d'un hypernephrome avec un anticorps humain anti-tnf ou un fragment de cet anticorps
WO2005077397A3 (fr) Procedes et compositions pour le traitement de maladies vasculaires

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580049931.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 561841

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 186307

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/011975

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2603359

Country of ref document: CA

Ref document number: 2008504018

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12007502135

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 07105853

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2005858723

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005339797

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077024874

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 4142/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200702093

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2005339797

Country of ref document: AU

Date of ref document: 20051222

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0520168

Country of ref document: BR

Kind code of ref document: A2